Dr. Darren Ross Gitelman, MD

Dr. Gitelman practices at United Therapies - Park Ridge in Park Ridge, Illinois.

Dr. Gitelman's NPI, 1164530804, was assigned on August 25, 2006. Dr. Gitelman graduated from Washington University School of Medicine in 1985. Dr. Gitelman holds Illinois license 036-088638.

Dr. Gitelman's primary practice is United Therapies - Park Ridge, at 1875 W Dempster St, Park Ridge, IL 60068. The practice phone is (847) 544-5853.

Dr. Gitelman's primary practice is United Therapies - Park Ridge in Park Ridge, Illinois. Dr. Gitelman is also affiliated with Advocate Lutheran General Hospital. The medical group on file is Dreyer Medical Clinic (Advocate Medical Group). Dmand AI also links Dr. Gitelman to 5 more hospitals, 2 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gitelman practices, 10 sites in all. Vendor and product names are available with a free account.

Behavioral neurology and neuropsychiatry is Dr. Gitelman's primary specialty in the NPI Registry, under taxonomy code 2084B0040X. Dmand AI has Dr. Gitelman's licenses on file in 2 states: Illinois and Wisconsin.

CMS data shows 1,055 Medicare services from Dr. Gitelman across 7 procedure codes in 2024, for 337 Medicare patients. Medicare paid $62,660 for them. Every service was in an office.

CMS counts 337 Medicare patients who saw Dr. Gitelman in 2024. The largest group is 75 to 84, with 161 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gitelman's median patient age at 79, with 61% women.

In 2024, Dr. Gitelman wrote 1,854 Medicare Part D claims for 361 patients. 97% of them were for generic drugs. CMS names the drug for 1,752 of them, across 20 drugs with 11 or more claims each, at $91,062 in total drug cost. In 2023, CMS named 1,816 claims across 18 drugs.

Dr. Gitelman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gitelman as offering telehealth.

Dmand AI links 22 papers to Dr. Gitelman, published from 2012 to 2024. 2013 was the busiest year, with 2. The most frequent topics are Magnetic Resonance Imaging, Brain and Brain Mapping. Dr. Gitelman has published most often in J Neurosci. Dr. Gitelman's most frequent co-authors are Neelum T. Aggarwal, MD, Hermine Isabel Brunner, MD and Maryjo L. Cleveland, MD.

Dmand AI links Dr. Gitelman to 5 clinical trials. 2 are still active or recruiting. Conditions studied include Alzheimer Disease, Cognitive Dysfunction and Tauopathies. Open Payments lists research payments to Dr. Gitelman that name 1 trial.

CMS Open Payments shows 90 general payments to Dr. Gitelman from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 86% of the total. Merck Sharp & Dohme Corporation paid the most, $58,554. It also lists 5 research payments totaling $44,348 from 2019 to 2023, naming 1 clinical trial.

Dr. Gitelman graduated from Washington University School of Medicine in 1985.